DVT: deep vein thromboembolism PE: pulmonary embolism; VTE: venous thromboembolism.
*Absolute risk of DVT in hospitalized patients. Rates based on objective diagnostic testing for DVT in patients not receiving thromboprophylaxis.10
*Study included 1,102 hospitalized patients older than 40 years, with congestive heart failure, acute respiratory failure that did not require ventilatory support, or one of the following medical conditions if it was associated with at least one additional risk factor for VTE: acute infection without septic shock; acute rheumatic disorders, including acute lumbar pain or sciatica or vertebral compression (caused by osteoporosis or a tumor), acute arthritis of the legs, or an acute episode of rheumatoid arthritis in the legs; or an episode of inflammatory bowel disease."
References:
1. Steering Committee for World Thrombosis Day (ISTH).J Thromb Haemost. 2014;12(10):1580-1590.
2. Lozano R, et al. Lancet. 2012;380(9859):2095-2128.
3. World Thrombosis Day 2021 Understanding Thrombosis, International Society on Thrombosis and Haemostasis. Available at: https://www.worldthrombosisday.org/issue/thrombosis. Accessed July 2021.
4. Cohen AT, et al Lancet. 2008;371(9610):387-394.
5. Fernandez MM, et al. Clinicoecon Outcomes Res. 2015;7:451-462
6. Heit JA. J Thromb Haemost. 2005;3(8):1611-1617.
7. Kahn SR, et al. Chest 2012;141(2 Suppl):e195S-e226S.
8. Shahi A, et al. J Arthroplasty. 2017;32(4):1063-1066.
9. Spyropoulos AC, et al. J Manag Care Pharm. 2007;3(6):475-486
10. Geerts WH, et al. Chest. 2004;126(3 Suppl):338S-400S.
11. Samama MM, et al. N Engl J Med. 1999;341:793-800.
12. White RH, et al.Thromb Haemost. 2003;90(3):446-455.
13. Spyropoulos AC, et al. Thromb Haemost. 2017;117(9):1662-1670.
14. Skeik N, et al. Ann Vasc Dis. 2020;13(1):38-44.
15. Mahan CE, et al.Thromb Haemost. 2012;108(2):291-302.
16. Amin A, et al. Clin Appl Thromb Hemost. 2019;25:1076029618823287.
17. Amin AN, et al. Thromb Haemost. 2010;104(5):955-961.
18. Amin AN, et al. J Hosp Med. 2012;7(3):231-238
19. Najjar PA, et al. J Am Coll Surg. 2016;223(6):804-813.
20. Bouras G, et al. PLoS One. 2015;10(12):E0145759.
Frequently Asked Questions
COMING SOON
Browse through medical articles
COMING SOON
Browse through on-demand medical videos
COMING SOON
Listen through medical discussions
COMING SOON
Browse through different medical cources
COMING SOON
Explore upcoming medical events
COMING SOON
Explore medical resources
COMING SOON
MAT-PH-2500061 | Ver 2.0 | DA 02-2025 | DM 02-2025
Adverse events & product safety
If you experience any adverse event, i.e., anu unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust
Adverse events & product safety
If you experience any adverse event, i.e., anu unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust
Adverse events & product safety
If you experience any adverse event, i.e., anu unfavorable and unintended sign (an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medical product, please email it to PV.Philippines@sanofi.com
For Data Privacy requests and concerns:
Sanofi General Medicines (under sanofi-aventis Philippines, Inc.) and Sanofi Vaccines (under Sanofi Pasteur, Inc.): OneTrust